Suartz C, Cordeiro M, Botelho L, Gallucci F, Cho D, de Arruda Pessoa F
World J Urol. 2024; 42(1):155.
PMID: 38483580
DOI: 10.1007/s00345-024-04798-5.
Samara M, Vlachostergios P, Thodou E, Zachos I, Mitrakas L, Evmorfopoulos K
Int J Mol Sci. 2023; 24(22).
PMID: 38003433
PMC: 10671612.
DOI: 10.3390/ijms242216243.
Riveros C, Ranganathan S, Haque W, Huang E, Xu J, Kulkarni G
Can Urol Assoc J. 2023; 18(2):17-24.
PMID: 37931278
PMC: 10841558.
DOI: 10.5489/cuaj.8386.
Chen G, Fan X, Wang T, Zhang E, Shao J, Chen S
Eur Radiol. 2023; 33(12):8821-8832.
PMID: 37470826
DOI: 10.1007/s00330-023-09960-y.
Ji J, Yao Y, Sun L, Yang Q, Zhang G
J Cancer Res Clin Oncol. 2023; 149(12):10911-10923.
PMID: 37318590
PMC: 10423104.
DOI: 10.1007/s00432-023-04978-7.
En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
Yanagisawa T, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y
Ann Surg Oncol. 2023; 30(6):3820-3828.
PMID: 36897417
DOI: 10.1245/s10434-023-13227-7.
Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).
Malkiewicz B, Gurwin A, Karwacki J, Nagi K, Knecht-Gurwin K, Hober K
Cancers (Basel). 2022; 14(21).
PMID: 36358705
PMC: 9656528.
DOI: 10.3390/cancers14215286.
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer.
Katayama S, Schuettfort V, Pradere B, Mori K, Mostafaei H, Quhal F
J Cancer Res Clin Oncol. 2022; 148(11):3091-3102.
PMID: 34997350
PMC: 9508199.
DOI: 10.1007/s00432-021-03887-x.
Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
Laukhtina E, Schuettfort V, DAndrea D, Pradere B, Mori K, Quhal F
Mol Carcinog. 2021; 61(1):5-18.
PMID: 34587660
PMC: 9293216.
DOI: 10.1002/mc.23355.
Predictive Nomogram and Risk Factors for Lymph Node Metastasis in Bladder Cancer.
Tian Z, Meng L, Wang X, Diao T, Hu M, Wang M
Front Oncol. 2021; 11:690324.
PMID: 34222019
PMC: 8242250.
DOI: 10.3389/fonc.2021.690324.
Combining Multiparametric MRI Radiomics Signature With the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer.
Zheng Z, Xu F, Gu Z, Yan Y, Xu T, Liu S
Front Oncol. 2021; 11:619893.
PMID: 34055600
PMC: 8155615.
DOI: 10.3389/fonc.2021.619893.
Nomograms in Urologic Oncology: Lights and Shadows.
Morlacco A, Modonutti D, Motterle G, Martino F, Dal Moro F, Novara G
J Clin Med. 2021; 10(5).
PMID: 33801184
PMC: 7957873.
DOI: 10.3390/jcm10050980.
A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.
Schuettfort V, DAndrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K
BJU Int. 2021; 129(2):182-193.
PMID: 33650265
PMC: 9291893.
DOI: 10.1111/bju.15379.
A Machine Learning-Based Investigation of Gender-Specific Prognosis of Lung Cancers.
Wang Y, Liu S, Wang Z, Fan Y, Huang J, Huang L
Medicina (Kaunas). 2021; 57(2).
PMID: 33499377
PMC: 7911834.
DOI: 10.3390/medicina57020099.
Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.
Grossmann N, Schuettfort V, Pradere B, Moschini M, Quhal F, Mostafaei H
Onco Targets Ther. 2021; 14:315-324.
PMID: 33488094
PMC: 7814246.
DOI: 10.2147/OTT.S242248.
Trends of incidence and prognosis of upper tract urothelial carcinoma.
Wu J, Chen S, Wu X, Mao W, Wang Y, Xu B
Bosn J Basic Med Sci. 2020; 21(5):607-619.
PMID: 33357210
PMC: 8381214.
DOI: 10.17305/bjbms.2020.5345.
Development and validation of prognostic nomogram for germ cell testicular cancer patients.
Mao W, Wu J, Kong Q, Li J, Xu B, Chen M
Aging (Albany NY). 2020; 12(21):22095-22111.
PMID: 33136554
PMC: 7695357.
DOI: 10.18632/aging.104063.
Plasma Fibrinogen Predicts the Prognosis of Bladder Cancer Patients After Radical Cystectomy.
Yang S, Guan H, Wang S, Wu H, Sun W, Chen Z
Cancer Manag Res. 2020; 12:9303-9314.
PMID: 33061620
PMC: 7532920.
DOI: 10.2147/CMAR.S269244.
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?.
Wettstein M, Naimark D, Hermanns T, Herrera-Caceres J, Ahmad A, Jewett M
Cancer Med. 2020; 9(10):3287-3296.
PMID: 32163677
PMC: 7221312.
DOI: 10.1002/cam4.2980.
Combining DWI radiomics features with transurethral resection promotes the differentiation between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer.
Xu S, Yao Q, Liu G, Jin D, Chen H, Xu J
Eur Radiol. 2019; 30(3):1804-1812.
PMID: 31773297
DOI: 10.1007/s00330-019-06484-2.